Shuttle Pharmaceuticals Holdings, Inc. cash flow to debt ratio of -4.08K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Shuttle Pharmaceuticals Holdings, Inc.'s free cash flow has decreased 29.40% from $-7.33M last year to $-9.48M, signaling decreasing performance

Shuttle Pharmaceuticals Holdings, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Shuttle Pharmaceuticals Holdings, Inc.'s debt has decreased relative to shareholder equity from 1.65 last year to 0.06 today, signaling strengthened financials

Shuttle Pharmaceuticals Holdings, Inc. has a net cash position, so leverage is healthy.

Shuttle Pharmaceuticals Holdings, Inc.'s interest coverage ratio is -157.45, which means that the company struggles to meet interest obligations, signaling financial risk.

Shuttle Pharmaceuticals Holdings, Inc. has insufficient data to evaluate this check.

Shuttle Pharmaceuticals Holdings, Inc.'s short-term liabilities of $7.97M exceed its short-term assets of $502.91K, signaling financial risk

Shuttle Pharmaceuticals Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -408.33%, is lower than 15.00%, indicating bad performance

Shuttle Pharmaceuticals Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Shuttle Pharmaceuticals Holdings, Inc. has insufficient public price history to evaluate earnings stability.

Shuttle Pharmaceuticals Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Shuttle Pharmaceuticals Holdings, Inc. has negative free cash flow, indicating cash burn

Shuttle Pharmaceuticals Holdings, Inc.'s yearly earnings has decreased 28.18% since last year from $-9.14M to $-11.72M, signaling decreasing performance

Shuttle Pharmaceuticals Holdings, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -312.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Shuttle Pharmaceuticals Holdings, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Shuttle Pharmaceuticals Holdings, Inc. has insufficient public price history to evaluate revenue consistency.

Shuttle Pharmaceuticals Holdings, Inc. has insufficient public price history to evaluate ROE consistency.

Shuttle Pharmaceuticals Holdings, Inc. has insufficient data to evaluate this check.

Shuttle Pharmaceuticals Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Shuttle Pharmaceuticals Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Shuttle Pharmaceuticals Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Shuttle Pharmaceuticals Holdings, Inc. has insufficient data to evaluate this check.

Shuttle Pharmaceuticals Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Shuttle Pharmaceuticals Holdings, Inc. has a price-to-book ratio of 0.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Shuttle Pharmaceuticals Holdings, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue